SCHEMBL4423803

SCHEMBL4423803

CCn1c(=O)c(-c2cc(NC(=O)Nc3cc(C(C)(C)C)on3)c(F)cc2C)cc2cnc(N)cc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.59
RAF1 P04049 5/20 0.59
KDR P35968 5/20 0.59
KRAS P01116 4/20 0.59
MAP2K2 P36507 3/20 0.59
MAP2K1 Q02750 3/20 0.59
KIT P10721 1/20 0.49
PDGFRA P16234 1/20 0.49
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
FLT3 P36888 8/20 0.42
SRC P12931 2/20 0.41
BTK Q06187 1/20 0.41
MAPK14 Q16539 3/20 0.41
MAPK13 O15264 2/20 0.41
CSF1R P07333 1/20 0.40
ABL1 P00519 1/20 0.40
FYN P06241 1/20 0.40
ARAF P10398 1/20 0.40
EPHA2 P29317 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4553396 0.91 RAF1 (0.73) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5061289 0.88 BRAF (0.65) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5061796 0.85 RAF1 (0.59) BRAFRAF1KDRKRASMAP2K2
SCHEMBL15000064 0.84 BRAF (0.61) BRAFRAF1KDRKRASMAP2K2
SCHEMBL5057559 0.83 RAF1 (0.62) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4419605 0.83 BRAF (0.51) BRAFRAF1KDRKRASMAP2K2
SCHEMBL14999897 0.83 KIT (0.66) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4424647 0.82 BRAF (0.61) BRAFRAF1KDRKRASMAP2K2
SCHEMBL14999758 0.80 KIT (0.58) BRAFRAF1KDRKRASMAP2K2
SCHEMBL4416682 0.80 RAF1 (0.58) BRAFRAF1KDRKRASMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.